Brandon Smaglo

7PUBLICATIONS
45CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 02, 2026
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.

Benjamin L Musher, Spyridoula Vasileiou, Brandon G Smaglo

|Sep 30, 2025
Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates.

Valerie S Kalluri, Brandon G Smaglo, Krishnan K Mahadevan

|Mar 17, 2025
KRAS G12D -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients.

Valerie S LeBleu, Brandon G Smaglo, Krishnan K Mahadevan

|Feb 03, 2024
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.

Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury

|Aug 23, 2023
Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma.

Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury

|Apr 16, 2021
Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary.

Kanwal Raghav, Hyunsoo Hwang, Alexandre A Jácome

Pageof 2